Resources

Mar 2022
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
Garcia-Carbonero R, Bazan-Peregrino M, Gil-Martín M, Álvarez R, Macarulla T, Riesco-Martinez MC, Verdaguer H,Guillén-Ponce C, Farrera-Sal M, Moreno R, Mato-Berciano A, Maliandi MV, Torres-Manjon S, Costa M, Del Pozo N,Martínez de Villarreal J, Real FX, Vidal N, Capella G, Alemany R, Blasi E, Blasco C, Cascalló M, Salazar R.
J Immunother Cancer. 2022 Mar;10(3):e003255. doi: 10.1136/jitc-2021-003255.
Nov 2021
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects
Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, Álvarez R, Mato-Berciano A, Gimenez-Alejandre M, Morgado S,Rodríguez-García A, Maliandi MV, Riesco MC, Moreno R, Ginestà MM, Perez-Carreras M, Gornals JB, Prados S, PereaS, Capella G, Alemany R, Salazar R, Blasi E, Blasco C, Cascallo M, Hidalgo M.
J Immunother Cancer. 2021 Nov;9(11):e003254. doi: 10.1136/jitc-2021-003254.
Nov 2021
VCN-01 is an encouraging therapy against retinoblastoma
Guillem Pascual-Pasto, Miriam Bazan-Peregrino, Ana Mato-Berciano, Genoveva Correa, Maria Cuadrado-Vilanova, Víctor Burgueño-Sandoval, Patricia Alonso-Lopez, Silvia Torres-Manjon, Rafael Moreno, Jaume Catalá-Mora, Ramón Alemany, Manel Cascalló, Guillermo L. Chantada, Angel M. Carcaboso.
IOVC 2021
Apr 2021
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11
Mato-Berciano A, Morgado S, Maliandi MV, Farrera-Sal M, Gimenez-Alejandre M, Ginestà MM, Moreno R, Torres-Manjon S, Moreno P, Arias-Badia M, Rojas LA, Capellà G, Alemany R, Cascallo M, Bazan-Peregrino M.
J Control Release. 2021 Apr 10;332:517-528. doi: 10.1016/j.jconrel.2021.02.035. Epub 2021 Mar 3.
May 2019
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial
Kokai-Kun JF, Roberts T, Coughlin O, Le C, Whalen H, Stevenson R, Wacher VJ, Sliman J.
Lancet Infect Dis. 2019 May;19(5):487-496. doi: 10.1016/S1473-3099(18)30731-X. Epub 2019 Mar 15.
Jan 2019
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolyticadenovirus VCN-01
Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K,Correa G, Paco S, Vila-Ubach M, Cuadrado-Vilanova M, Castillo-Ecija H, Botteri G, Garcia-Gerique L, Moreno-GilabertH, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, DozF, Cassoux N, Chapeaublanc E, Torrebadell M, Roldan M, König A, Suñol M, Claverol J, Lavarino C, Carmen de T, Fu L,Radvanyi F, Munier FL, Catalá-Mora J, Mora J, Alemany R, Cascalló M, Chantada GL, Carcaboso AM.
Sci Transl Med. 2019 Jan 23;11(476):eaat9321. doi: 10.1126/scitranslmed.aat9321.